The Early Signs Before McKesson Stock’s 44% Rise

MCKYTD+33.5%SPYYTD+8.2%XLVYTD+21.1%
Analyze MCK →

Today’s big story: Anthropic IPO: Priced For 2031, Or 2036?

McKesson (MCK) stock returned 43.6% from May 19 to November 17, 2026, against 0.37% for the S&P 500. Over that window, McKesson raised its annual profit forecast in August on strength in its oncology and specialty drug businesses. It raised its earnings guidance again in November. Yet the shares had fallen 11.3% in the six months before. So what was already public about McKesson’s business before May 19, while the shares were falling?

Image from Pixabay

What Was Public About McKesson Before May 19?

Management was already talking about cancer care on its fiscal Q2 2026 call, held November 5, 2025. It described its work integrating Florida Cancer Specialists and PRISM Vision. That was a sign McKesson was growing its cancer and eye-care practice networks. The cancer-care part is the same oncology business behind the August forecast raise. The call took place more than six months before the window opened.

Profit followed. McKesson reported its fiscal Q3 2026 results on February 4, 2026, and raised its full-year adjusted earnings guidance. In the quarter ended March 31, 2026, filed on May 8, McKesson’s operating margin reached 2.3%, against 1.8% in the same quarter a year earlier.

Sales told a different story over the same stretch. Revenue growth slowed from 23.4% in the quarter ended June 2025 to 6.0% in the quarter ended March 2026. So the signs were readable, but they were about cancer care and profit rather than sales. The shares jumped 16.5% on February 5, the day after the guidance raise. They fell 7.2% on May 6 and ended the six months before May 19 lower.

What Investors Now Pay For In McKesson

Investors now pay 27.0 times McKesson’s earnings over the last twelve months, against 22.0 for the S&P 500. McKesson’s shares were not the only ones to rise. Cardinal Health returned 40.0% over the same window, close to McKesson’s return. So much of the rise was shared with a peer, not driven by McKesson’s own business alone.

Inside the business, the oncology side stood out. Management said on its latest call, on November 4, that oncology and multispecialty revenue rose 24% to $15 billion in fiscal Q2 2027. McKesson’s total revenue grew 7.6% that quarter, to $111 billion. So oncology is still a small part of the company, but it grew about three times as fast as the whole.

Is McKesson’s Oncology Growth Still Building?

McKesson’s oncology business is still growing quickly, but management expects slower growth than last year. Oncology and multispecialty revenue grew 20.9% in fiscal 2025 and 31.4% in fiscal 2026, the year ended March 31, 2026. For fiscal 2027, management expects that segment’s revenue to grow 20% to 24%.

From here, the segment also holds an acquisition. McKesson closed its purchase of Precision Medicine Group the week of the November 4 call. That business will report within oncology and multispecialty. So the segment’s next growth rate will include the purchase, not only growth in the existing business. That growth rate is the number to watch when McKesson next reports, expected in February 2027.

Even someone who read McKesson’s signs correctly had to sit through a falling price first. That kind of wait is easier when your money rests on many strong companies rather than on one.

Why Own One Leader When You Can Own 30?

If you like finding quality companies like McKesson, the Trefis High Quality (HQ) Portfolio holds 30 of them in equal weight, and has returned more than 105% since its September 2020 launch. You’re welcome to look inside.

See The HQ Portfolio

Spot an error or want more like this? Tell us in 10 seconds.